| Abstract | Imipenem/cilastatin sodium (MK-0787/MK-0791) was evaluated for its safety, efficacy and pharmacokinetics in children. Thirty cases of bacterial infections were treated with MK-0787/MK-0791 at a daily dose of 40 to 222 mg/kg for 2.25 to 13 days. Clinical cure rate was 93% and bacteriological efficacy rate was 88%. Treated diseases included severe tonsillitis due to mixed anaerobic infections, pneumonia, sepsis, brain abscess and soft tissue infections. Two cases, one with periosteomyelitis due to methicillin-resistant S. aureus and the other with pulmonary abscess due to Haemophilus influenzae (other than type b), failed to respond to the MK-0787/MK-0791 therapy. The serum half-life of MK-0787 was 0.892 hour in children with normal renal functions. An episode of convulsions in a case of sepsis with bacterial croup and brain edema was considered to be associated with the MK-0787/MK-0791 therapy. From the present study, MK-0787/MK-0791 appears a safe and effective antibiotic when used in children with a variety of bacterial infections. |
| Authors | H Meguro, O Arimasu, M Kobayashi, H Shiraishi, R Fujii, K Izumi |
| Journal | The Japanese journal of antibiotics
(Jpn J Antibiot)
Vol. 39
Issue 7
Pg. 1715-32
(Jul 1986)
ISSN: 0368-2781 JAPAN |
| PMID | 3464775
(Publication Type: English Abstract, Journal Article)
|
| Chemical References |
- Cyclopropanes
- Drug Combinations
- Thienamycins
- Imipenem
- Cilastatin
|
| Topics |
- Bacteria
(drug effects)
- Bacterial Infections
(drug therapy)
- Child
- Child, Preschool
- Cilastatin
- Cyclopropanes
(administration & dosage, adverse effects, metabolism)
- Drug Combinations
- Female
- Humans
- Imipenem
- Infant
- Kinetics
- Male
- Thienamycins
(administration & dosage, adverse effects, metabolism)
|
